	US 11,866,510 B2
	Chimeric antigen receptor with single domain antibody
Brian McGuinness, Cambridge (GB); and Colette Johnston, Cambridge (GB)
Assigned to CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
Appl. No. 16/099,099
Filed by CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
PCT Filed May 8, 2017, PCT No. PCT/GB2017/051272 § 371(c)(1), (2) Date Nov. 5, 2018, PCT Pub. No. WO2017/191476, PCT Pub. Date Nov. 9, 2017.
Claims priority of application No. 1607968 (GB), filed on May 6, 2016.
Prior Publication US 2019/0144561 A1, May 16, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); C07K 16/30 (2006.01); C07K 16/00 (2006.01)

CPC C07K 16/3069 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 16/00 (2013.01); C12N 5/0646 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/569 (2013.01); C07K 2319/03 (2013.01)]

13 Claims

1. An isolated chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain and an intracellular signalling domain wherein said binding domain comprises a first single human variable heavy chain (V_H) domain antibody that comprises SEQ ID NO. 23 or 24, and a second single human variable heavy chain (V_H) domain antibody wherein said first single human VH domain antibody binds to human Prostate-specific membrane antigen (PSMA) and said second single human VH domain antibody binds to a second target.